BioLife Solutions, Inc.
BLFS
$20.12
-$0.55-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.90% | 73.28% | 54.47% | 23.11% | -1.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.90% | 73.28% | 54.47% | 23.11% | -1.59% |
| Cost of Revenue | 48.82% | 530.64% | 214.78% | 26.76% | -17.95% |
| Gross Profit | 31.06% | 25.69% | 22.63% | 21.39% | 9.06% |
| SG&A Expenses | 13.59% | 33.03% | 15.83% | -1.21% | -11.46% |
| Depreciation & Amortization | 727.00% | -77.90% | -85.40% | -90.08% | -92.53% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.33% | 69.06% | 32.73% | -4.14% | -22.04% |
| Operating Income | 43.96% | 22.95% | 79.44% | 88.58% | 82.53% |
| Income Before Tax | -53.10% | -823.03% | -24.19% | 53.36% | 52.23% |
| Income Tax Expenses | 228.95% | 183.39% | 184.00% | 58.59% | -58.33% |
| Earnings from Continuing Operations | -54.32% | -743.28% | -25.80% | 53.32% | 52.38% |
| Earnings from Discontinued Operations | 178.61% | 124.04% | 117.37% | 91.51% | 77.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.23% | 93.26% | 92.63% | 83.86% | 70.32% |
| EBIT | 43.96% | 22.95% | 79.44% | 88.58% | 82.53% |
| EBITDA | -47.94% | -43.14% | 893.58% | 153.02% | 130.24% |
| EPS Basic | 77.99% | 94.19% | 93.40% | 84.29% | 71.38% |
| Normalized Basic EPS | 139.88% | 120.75% | 93.90% | 90.98% | 82.51% |
| EPS Diluted | 76.16% | 93.12% | 92.91% | 83.73% | 70.86% |
| Normalized Diluted EPS | 138.84% | 119.60% | 93.77% | 90.92% | 82.46% |
| Average Basic Shares Outstanding | 3.66% | 3.88% | 4.41% | 4.91% | 5.37% |
| Average Diluted Shares Outstanding | 3.78% | 5.07% | 5.18% | 5.69% | 6.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |